A new tool for the chemical genetic investigation of the <em>Plasmodium falciparum</em> Pfnek-2 NIMA-related kinase by Mitcheson DF et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Mitcheson DF, Bottrill AR, Carr K, Coxon CR, Cano C, Golding BT, Griffin RJ, Fry 
AM, Doerig C, Bayliss R, Tobin AB. 
A new tool for the chemical genetic investigation of the Plasmodium 
falciparum Pfnek-2 NIMA-related kinase. 
Malaria Journal 2016, 15, 1-12 
 
Copyright: 
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give appropriate credit to the original 
author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were 
made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ 
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. 
 
DOI link to article: 
http://dx.doi.org/10.1186/s12936-016-1580-3 
 
Date deposited:   
14/12/2016 
  
Mitcheson et al. Malar J  (2016) 15:535 
DOI 10.1186/s12936-016-1580-3
METHODOLOGY
A new tool for the chemical genetic 
investigation of the Plasmodium falciparum 
Pfnek-2 NIMA-related kinase
Deborah F. Mitcheson1, Andrew R. Bottrill2, Katherine Carr1, Christopher R. Coxon3, Celine Cano4, 
Bernard T. Golding4, Roger J. Griffin4, Andrew M. Fry1, Christian Doerig5, Richard Bayliss6 and Andrew B. Tobin7*
Abstract 
Background: Examining essential biochemical pathways in Plasmodium falciparum presents serious challenges, as 
standard molecular techniques such as siRNA cannot be employed in this organism, and generating gene knock-outs 
of essential proteins requires specialized conditional approaches. In the study of protein kinases, pharmacological 
inhibition presents a feasible alternative option. However, as in mammalian systems, inhibitors often lack the desired 
selectivity. Described here is a chemical genetic approach to selectively inhibit Pfnek-2 in P. falciparum, a member of 
the NIMA-related kinase family that is essential for completion of the sexual development of the parasite.
Results: Introduction of a valine to cysteine mutation at position 24 in the glycine rich loop of Pfnek-2 does not 
affect kinase activity but confers sensitivity to the protein kinase inhibitor 4-(6-ethynyl-9H-purin-2-ylamino) ben-
zene sulfonamide (NCL-00016066). Using a combination of in vitro kinase assays and mass spectrometry, (including 
phosphoproteomics) the study shows that this compound acts as an irreversible inhibitor to the mutant Pfnek2 likely 
through a covalent link with the introduced cysteine residue. In particular, this was shown by analysis of total protein 
mass using mass spectrometry which showed a shift in molecular weight of the mutant kinase in the presence of the 
inhibitor to be precisely equivalent to the molecular weight of NCL-00016066. A similar molecular weight shift was 
not observed in the wild type kinase. Importantly, this inhibitor has little activity towards the wild type Pfnek-2 and, 
therefore, has all the properties of an effective chemical genetic tool that could be employed to determine the cel-
lular targets for Pfnek-2.
Conclusions: Allelic replacement of wild-type Pfnek-2 with the mutated kinase will allow for targeted inhibition of 
Pfnek-2 with NCL-00016066 and hence pave the way for comparative studies aimed at understanding the biological 
role and transmission-blocking potential of Pfnek-2.
Keywords: Plasmodium falciparum, NIMA-related protein kinase (Nek), Covalent modification, Chemical genetics, 
Mass spectrometry
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Background
Despite the efficacy of artemisinin-based combination 
therapy (ACT) in the treatment of malaria, an estimated 
214 million cases and 438,000 malaria deaths occurred 
globally in 2015 [1]. Together with alarming recent 
reports of the emergence of resistance to ACT [2–4], 
this highlights the urgent need for novel anti-malarial 
treatments.
Protein phosphorylation is known to play key roles in 
the progression of the Plasmodium life cycle through 
both the human host and the mosquito vector. Thirty-six 
of the approximately 90 kinases encoded in the parasite’s 
genome appear to play essential roles in key parasite pro-
cesses, including invasion, proliferation and cyto-adher-
ence [5], suggesting that targeting these protein kinases 
has therapeutic value [6]. Despite this, and the fact that 
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protein kinases have proven successful targets in a num-
ber of human diseases, most notably cancer [7], no pro-
tein kinase inhibitors have yet reached the clinic for the 
treatment of malaria.
Amongst the protein kinases that play essential roles in 
the parasite’s life cycle are Pfnek-1 and Pfnek-2, members 
of the NIMA-related protein kinase family (which con-
sists in total of four members Pfnek1-4) [8–12]. Whereas 
Pfnek-1 is considered essential for the completion of the 
erythrocytic asexual cycle [10, 12], Pfnek-2 is dispensable 
for asexual proliferation but essential for the completion of 
sexual development of the parasite in the mosquito vector 
[9]. It therefore represents a potential target for transmis-
sion-blocking drugs. Phylogenetic analysis of Plasmodium 
Neks [8] indicates that Pfnek-2 and Pfnek-4 form a cluster 
that is loosely associated with human Hsnek4.
In humans, there are 11 members of the Nek family 
with various roles in several processes. The involvement 
of human Hsnek2 in cell cycle regulation events, includ-
ing centrosome disjunction, spindle assembly and the 
DNA damage response [13], has suggested that inhibitors 
to Hsnek2 might have clinical efficacy in the treatment of 
cancer [14–19]. There have been considerable efforts to 
generate inhibitors to Hsnek2 through the implementa-
tion of structure-based design to exploit unique struc-
tural features of the ATP binding pocket [20–23]. This 
has lead to the development of a compound, 4-(6-ethy-
nyl-9H-purin-2-ylamino) benzene sulfonamide (NCL-
00016066), that acts as an irreversible inhibitor of human 
Hsnek2. Structural studies have established that the 
inhibitory activity of NCL-00016066 results from the 
presence of the ethynyl group which forms an irrevers-
ible covalent link with cysteine-22 in the glycine rich loop 
[24].
Although phylogenetic studies have indicated that 
Hsnek2 and Pfnek-2 are not orthologues [8] they do how-
ever share several common features, including a large 
methionine gatekeeper residue, a bulky phenylalanine 
which restricts access for ATP-competitive protein kinase 
inhibitors and the conserved DaFG……..A/SPE sequence 
within the activation loop. One difference however is that 
parasite Pfneks lack the cysteine in the glycine rich loop 
with which NCL-00016066 forms a covalent linkage in 
Hsnek2. This position in Pfnek-2 (amino acid 24) is occu-
pied by a valine. It can, therefore, be predicted that in 
the absence of a cysteine in position 24, NCL-00016066 
would act as a very weak inhibitor of Pfnek-2 activity. 
Furthermore, by replacing valine 24 (Val24) in Pfnek-2 
with a cysteine, a mutant kinase would be generated that 
would be sensitive to NCL-00016066 inhibition. The final 
prediction would be that in the cysteine mutant, NCL-
00016066 would act in an irreversible manner by forming 
a covalent link with the substituted cysteine.
The data presented here show that these predictions 
are correct and that by substituting Val24 for cysteine 
in Pfnek-2, it is possible to generate a chemical genetic 
tool that could be used to dissect the in vivo function of 
Pfnek-2.
Methods
Materials
Unless otherwise stated all biochemicals and reagents 
were from Sigma-Aldrich.
Parasite culture and treatment with NCL‑00016066
Plasmodium falciparum blood stage 3D7 (wild type) 
parasites were grown (as previously described [25]) in 
complete RPMI 1640 medium (RPMI 1640 medium 
with 2 mM l-glutamine, 25 mM HEPES, 2 g/l NaHCO3, 
27.2  mg/l hypoxanthine and 0.5% Albumax II, pH 7.4) 
using O+ human red blood cells at 37  °C in an incuba-
tor with 5% CO2, 5% O2 and 90% N2. Sorbitol treatment 
was used to synchronize the parasites [26]: parasites were 
treated with 5% sorbitol for 20 min at room temperature 
to lyse trophozoite and schizont stage parasites. Dead 
parasites were removed by two washes with incomplete 
RPMI medium (RPMI 1640 medium with 2  mM  l-glu-
tamine, 25 mM HEPES, pH 7.4). Following sorbitol treat-
ment parasites were transferred to complete RPMI 1640 
medium.
To determine the viability of parasites cultures that 
had reached the trophozoite stage, they were diluted to 
0.3% parasitaemia and 2% haematocrit and treated with 
increasing concentrations of NCL-00016066 in a 96-well 
round bottom plate (Corning) and incubated for 72 h in 
an incubator with 5% CO2, 5% O2 and 90% N2. Several 
wells were treated with either 10% DMSO or 20 µM chlo-
roquine as controls. They were then placed in a −80  °C 
freezer prior to lactate dehydrogenase (LDH) and SYBR 
Green I assays.
SYBR Green I assay
Frozen plates were thawed for approximately 4  h at 
room temperature and 100 µl of SYBR Green I reaction 
buffer (20 mM Tris, 5 mM EDTA, pH 7.5, 0.08% Triton 
X-100, 0.008% saponin and 0.1 µl/ml SYBR Green I) was 
added to each well on the plate. The plate was shaken for 
10 min to ensure mixing and incubated for 1 h at room 
temperature in the dark. The fluorescence was read 
using a CLARIOstar plate reader. (BMG Labtech GmbH, 
Germany).
Lactate dehydrogenase (LDH) assay
Frozen plates were thawed for approximately 4  h at 
room temperature and 150  µl of LDH reaction buffer 
[100  mM Tris–HCl, pH 8.0, 150  mM sodium lactate, 
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150  µM APAD (3-Acetylpyridine adenine dinucleotide), 
180 µM Nitrotetrazolium Blue Chloride, 0.7% Tween-20 
and diaphorase (0.3 units/assay)] was added to each well 
on the plate. The plate was shaken for 10 min to ensure 
mixing and the absorbance at 595  nm was obtained 
using a CLARIOstar plate reader. (BMG Labtech GmBH, 
Germany).
Pfnek‑2 plasmid design
The synthetic full-length coding sequence for Pfnek-2 
(PlasmoDB identifier PF3D7_0525900) was purchased 
(with codon optimization for Escherichia coli expres-
sion) from GeneArt™ Life Technologies. The codon 
optimized DNA sequence was as follows (the codon 
encoding V24 is highlighted in bold); ATGAGCAAAC-
CGAAAATGATCGGTCCGTATGAAGTTGTGAAAA-
GCATTGGTCGTGGTAGCTTTGGTATTGTTAC-
CGCAGTTAAAGATGAAAATGAAAAAATCTTT-
G TG AT TA A AG A AC TG G ATAT TAG C TG C AT-
GAATAACAAAGAAAAAATGAATGTGGTGAAT-
GAAATTCGTGCCCTGATTAAAATGAGCGTG-
CATCCGTTTATTGTGCGCTATAAAGAAGCCTTT-
GTTGAAGATTGCGTTCTGTATGTTGCGATG-
GATTATTGCATTAATGGTGATCTGGGCAAA-
GTGATCAAAAAACACAAAGAACTGGAAACCC-
CGATTCCTGAGAAAAAAATCAAACGTTGGCT-
GCTGCAGATTATTATGGCCATCAAATTCATTCAT-
GATAAAAAACTGATCCATCGTGATCTGAAATG-
CAATAACATCTTCCTGGATGAAAAAGAACGT-
GCCAAAATTGGTGATTTTGGTCTGGCCAAATT-
TAT C G A A C A G A C A G A A C A G A C C A ATA C C -
CTGTGTGGCACCATTGGTTATATGGCACCG-
GAAATTTGCAAAAATATCAATTACAGCTTCC-
CTGCCGATATTTGGAGCCTGGGTATTATTCT-
GTATGAACTGATTAGCCTGAAACCGCCTTT-
TAAAAGCAATAACAGCAATATGCTGAGCGTG-
GCCCAGAAAATTTGTGAAGATGAACCGGATC-
CGCTGCCGGATAGCTTTAGCAAAGATCTGAT-
TAATCTGTGCTATTGGATGCTGAAAAAAGATTG-
GAAAGATCGTCCGACCATCTACGATATTATCAG-
CACCGATTATATCCAGGATGAACTGCAGCTGTT-
TAAACGTGAAATGCTGCAAGAACGTAACAGCCA-
GATT.
The codon optimized sequence was cloned into a 
pET30a vector using NdeI and XhoI sites and a stop 
codon was added by site directed mutagenesis. The 
final construct used for protein expression contained 
an N-terminal His tag and a cleavable Tev sequence fol-
lowed by the full length Pfnek-2 sequence.
Cloning of Pfnek‑2 and site‑directed mutagenesis
The plasmid described above encoding wild type 
PfNek-2 was used as a template to generate Pfnek-2 
V24C by site directed mutagenesis. The follow-
ing primers were used forward (5′-gcattggtcgtg-
gtagctttggtatttgtaccgcagttaaaga-3′) and reverse 
(5′-tctttaactgcggtacaaataccaaagctaccacgaccaatgc-3′).
Bacterial protein expression
Full-length Pfnek-2 as a 6-HIS-tagged protein was 
expressed in E. coli BL21-Codon Plus(DE3)-RIPL strain 
(Agilent Technologies). Cells were treated with 1  mM 
IPTG when the optical density of the cell culture at 
600 nm reached 0.6, and protein expression was induced 
overnight at 18  °C. For purification, cells were lysed in 
buffer [50  mM bicine, pH 8.0, 150  mM NaCl, 20  mM 
Imidazole, 1% glycerol, 1  mM DTT, Protease Inhibi-
tor Cocktail (Roche)] [1 tablet per 10  ml (cOmplete™ 
ULTRA Tablets by Roche)] by sonication for 10 cycles of 
10 s bursts at 10 mA with a 30 s rest between each cycle. 
During sonication the cells were kept on ice. Lysates were 
then centrifuged at 20,000g for 30  min. The resulting 
supernatants were loaded onto a 0.5 ml pre-equilibrated 
Ni–NTA Superflow resin (Qiagen) column, washed with 
buffer (50 mM bicine, pH 8.0, 150 mM NaCl, 20 mM Imi-
dazole, 1% glycerol and 1  mM DTT) and proteins were 
eluted with the same buffer containing 400  mM Imida-
zole. Eluted proteins were dialysed against 50 mM bicine, 
pH 8.0, 150  mM NaCl, 1% glycerol and 1  mM DTT at 
4  °C overnight. Dialysed Pfnek-2 protein was aliquoted 
and stored at −80 °C.
In vitro Pfnek‑2 kinase assay
Recombinant His-tagged WT or V24C mutant Pfnek-2 
were assayed for protein kinase activity using myelin 
basic protein (MBP) as a substrate. 1.8  µg of either 
Pfnek-2 WT or Pfnek-2 V24C were pre-incubated 
at room temperature for 40  min with/without NCL-
00016066 (1, 10 or 20  µM) in Pfnek-2 buffer (10  mM 
bicine, pH 8.0, 40 mM NaCl, 1% glycerol, 10 mM MgCl2, 
4  mM imidazole, 1  mM DTT) in the presence of 5  µg 
MBP. The reaction was started by the addition of 5  µl 
200 µM ATP/32P-ATP (0.0185 MBq per reaction)—total 
volume 20  µl. Following incubation of 30  min at 37  °C, 
the reactions were stopped by adding 10 µl 2× Laemmli 
buffer and proteins were separated by SDS–PAGE on 
12% gels and stained with Coomassie blue. Dried gels 
were exposed to X-ray film.
NCL‑00016066 compound
The human Nek2 inhibitor, NCL-00016066 (gift from 
Professor Roger Griffin, University of Newcastle) was 
dissolved in DMSO to 10  mM and frozen in aliquots 
of 10 µl at −80 °C. These aliquots were kept in the dark 
and a fresh aliquot diluted prior to each kinase assay. All 
samples in each kinase assay were pre-incubated with 
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NCL-00016066 for 40 min at room temperature and the 
reaction initiated by the addition of ATP/32P-ATP as pre-
viously described above.
Immobilising Pfnek‑2 (wild type) and Pfnek‑2 (V24C) 
on Ni–NTA Superflow Beads—pre‑incubation 
with inhibitor NCL‑00016066
Recombinant Pfnek-2 wild type and Pfnek-2 V24C were 
purified as previously described and incubated (1:1) 
without/with 20  µM NCL-00016066 diluted in 10  mM 
bicine, pH 8.0, 40  mM NaCl, 10  mM MgCl2, 1% glyc-
erol, 4 mM imidazole, 1 mM DTT at room temperature 
for 30  min. 50  µl Ni–NTA Superflow resin (Qiagen) 
was added and the samples made up to 500 µl in buffer 
(10  mM bicine, pH 8.0, 40  mM NaCl, 10  mM MgCl2, 
1% glycerol, 4 mM imidazole, 1 mM DTT) and rotated 
for 1  h at room temperature. The beads were washed 
3× in 500 µl buffer for 5 min rotation and supernatants 
discarded. The in  vitro kinase assay protocol described 
above was followed and the enzyme immobilized on 
beads (washed and supernatant removed) is assumed to 
be 5 µl for the purpose of the kinase assay. During incu-
bation at 37 °C the beads were gently re-suspended every 
10 min.
Preparation of samples for mass spectroscopy
Recombinant Pfnek-2 wild type and Pfnek-2 V24C were 
purified as previously described except glycerol was 
absent from all buffers. The absence of glycerol had no 
effect on the activity of the enzyme and was only added 
to previous preparations to stabilize the enzyme. Glyc-
erol however interferes with the mass spectrometry and 
so was omitted here. Both wild type and mutant (V24C) 
Pfnek-2 were incubated (1:1) without/with 100  µM 
NCL-00016066 diluted in buffer (10 mM bicine, pH 8.0, 
40  mM NaCl, 10  mM MgCl2, 4  mM imidazole, 1  mM 
DTT) at room temperature prior to mass spectrometry 
analysis.
Mass spectrometry—identification of putative covalent 
bonding of NCL‑00016066 to Pfnek‑2
LC–MS was carried out using an RSLCnano HPLC sys-
tem (Thermo Scientific) coupled to an LTQ-Orbitrap-
Velos mass spectrometer (Thermo Scientific). Samples 
were loaded at 0.1  ml/min onto a Vydac C8 5  µm 250 
mm × 1 mm I.D. reverse phase column (Grace Davison). 
The protein was desalted for 10 min in the loading buffer 
(0.1% formic acid) before elution using a 10  min linear 
gradient from 3 to 96% B (80% acetonitrile/0.1% formic 
acid). The output of the column was sprayed directly into 
the H-ESI2 electrospray ion source of the mass spec-
trometer maintained at 5  kV. The ion trap was set to 
acquire 10 microscans over the m/z range 800–1200 Da 
in positive ion mode. The maximum injection time for 
MS was 50 ms and the AGC target setting was 3e4. Pro-
tein charge-state distributions were viewed using the 
Fig. 1 X-ray crystal structure of the ATP-binding domain of HsNek2 in complex with NCL-00016066 (determined at 2.0 Ǻ). a Chemical structure 
of NCL-00016066. b X-ray crystal structure of the ATP-binding domain (hinge region of kinase) of human nek2 in complex with NCL-00016066. 
Indicated is the presence of three predicted hydrogen bonds (arrows) between oxygens (red) and nitrogens (blue) within the hinge region and 
contained in NCL-00016066. The distances indicated are in angstroms. Also shown is the thioenol ether bond between cysteine 22 in Hsnek-2 and 
NCL-00016066 (yellow)
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Xcalibur program (version 2.1.0.1139, Thermo Scientific) 
and molecular weight calculations made using ESIprot 
[27].
Mass spectrometry analysis of Pfnek‑2 
autophosphorylation
Recombinant Pfnek-2 (4  µl of 13  mg/ml stock solution 
of enzyme) was incubated with/without 1  mM ATP in 
Pfnek-2 buffer (10 mM bicine, pH 8.0, 40 mM NaCl, 1% 
glycerol, 10  mM MgCl2, 4  mM imidazole, 1  mM DTT) 
for 30 min at 37 °C. The reaction was stopped by adding 
10 µl 2× Laemmli buffer and proteins were separated by 
SDS–PAGE on a 12% gel. The dye front was removed and 
the gel placed in fixing solution [7% glacial acetic acid in 
40% (v/v) methanol] for 1 h. The gel was stained with four 
parts colloidal blue to one part methanol and destained 
with 10% acetic acid in 25% (v/v). Protein bands were 
excised from the gel and cut into small pieces and washed 
three times with 200 μl of buffer B [20 ml 400 mM ammo-
nium bicarbonate (3.16 g/100 ml) with 100% acetonitrile 
in ratio 1:1]. The gel pieces were then washed twice with 
200 μl acetonitrile (100%) and gel pieces air dried.
The gel fragments were then incubated for 30  min at 
60 °C in 100 µl 10 mM DTT in 50 mM TEAB buffer, pH 
8.5. The liquid was removed and the fragments incubated 
in 100 µl 100 mM iodoacetamide in 50 mM TEAB buffer 
Fig. 2 Alignment of HsNek2/Pfnek-2 protein sequences and the viability of parasite cultures following exposure to NCL-00016066. a Alignment of 
the amino acid sequences of Hsnek2 and Pfnek-2. The conserved methionine gatekeeper (magenta) and the conserved phenylalanine (green) are 
shown, as are the conserved HRD sequence (yellow) with the conserved activation loop motifs DFG and APE/SPE (turquoise). The valine at position 
24 in Pfnek-2 is a cysteine in Hsnek2 and is highlighted in red. The identical amino acids between Hsnek-2 and Pfnek-2 are indicated with a asterisk 
(*), the highly conserved amino acids with two dots (:) and the conserved amino acids with one dot (.). b, c The viability of parasites in the presence 
of varying concentrations of NCL-00016066 as measured by (b) SYBR Green I and (c) LDH assays. As the parasites are chloroquine sensitive, chloro-
quine (20 μM) was included as a positive control while non-infected red blood cells, without inhibitor, and 10% DMSO were included as negative 
controls. The results are presented as the mean ± SEM. (n = 3)
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for 30  min at room temperature in the dark. The frag-
ments were washed twice in buffer B for 20 min, washed 
briefly in acetonitrile (100%) followed by a further addi-
tion of acetonitrile for 10 min at room temperature fol-
lowed by aspiration of the fluid and air drying. Trypsin 
solution (1 μg in 50 μl of 50 mM TEAB buffer per sam-
ple) was added and incubated at 37 °C overnight. The gel 
pieces were washed in 50 mM TEAB buffer for 5–10 min 
on a rotating platform. The digests and washes were com-
bined and dried completely in a SpeedVac. The samples 
were then enriched for phosphopeptides as described 
below.
IMAC enrichment of phosphopeptides for mass 
spectrometry
PHOS-Select iron affinity gel (Sigma) was equilibrated 
with 5  ×  1  ml IMAC load/wash buffer [0.25  M acetic 
acid, 30% (v/v) acetonitrile]. 500  µl IMAC load/wash 
buffer was added to completely dry samples and 50 µl of 
50% PHOS-Select slurry was added followed by rotating 
at room temperature for 1 h. Following incubation with 
IMAC beads, the samples were transferred onto Mobicol 
‘Classic’ spin columns (2B Scientific Ltd), centrifuged for 
30 s at 1000×g, and the flow-through (unbound peptides) 
collected and frozen. The IMAC beads were washed 
twice with 200  µl of IMAC load/wash buffer, once with 
200 µl of HPLC grade water and eluted twice with 100 µl 
of solution containing 22  µl ammonia solution (Fisher 
Chemical, 35% stock), 300  µl acetonitrile to a total vol-
ume of 1 ml with HPLC grade water. Eluates were con-
centrated to a small volume (15–20  µl) in a Speedvac 
centrifuge and submitted for mass spectrometry analysis.
Mass spectroscopy and data processing—identification 
of potential autophosphorylation sites
This was carried out as previously described [28] with one 
difference in that peptides were eluted from a reverse-
phase PicoFrit capillary column (75 µm i.d. ×  400 mm) 
over a period of 2 h.
Results
Characterization of Pfnek‑2 and Pfnek‑2 V24C mutant 
kinases
The compound NCL-00016066 (Fig.  1a) was origi-
nally developed as an inhibitor to human Hsnek2 [24]. 
A crystal structure of NCL-00016066 in complex with 
Hsnek2 was obtained, and confirmed that the inhibi-
tor formed a covalent linkage with Cys22 in the glycine 
rich loop through the ethynyl moiety of NCL-00016066 
(Fig. 1b). A crystal structure for Pfnek-2 is not currently 
available however amino acid sequence alignment of 
Hsnek2 with Pfnek-2 revealed that there are no cysteine 
residues within the glycine rich loop of Pfnek-2 (Fig. 2a); 
the equivalent position of Hsnek2 Cys22, in Pfnek-2, 
is occupied by Val24 (Fig.  2a). This would indicate that 
the parasiticidal activity of NCL-0016066 would be very 
low, which was indeed found to be the case with EC50 
values of 23.95  ±  2.50 and 35.63  ±  3.03  µM as meas-
ured by SYBR Green I and LDH parasite death assays, 
respectively (Fig.  2b, c). Substituting Pfnek-2 Val24 
with a cysteine created a mutant, Pfnek-2(V24C), that 
could be expressed in E. coli and affinity purified on a 
Ni–NTA chromatography column through a His-tag 
engineered into the N-terminus of the kinase. Purified 
Pfnek-2 and Pfnek-2(V24C) were resolved by SDS PAGE 
and appeared as a single band at approximately 38  kDa 
(Fig.  3a). Enzymatic activity of Pfnek-2 was assayed in 
in vitro kinase assays using α-casein or myelin basic pro-
tein (MBP) as exogenous substrate. Both wild type and 
mutant enzymes favoured MBP as a substrate (Fig.  3b) 
and appeared to display similar kinase activities. Subse-
quent experiments therefore used MBP as a substrate.
Effect of NCL‑00016066 on kinase activity
Having established the activity of the purified wild type 
and mutant kinases, we next tested the ability of NCL-
00016066 to inhibit kinase activity. Purified kinases 
were incubated with MBP in the presence of 10 or 1 µM 
NCL-00016066 (Fig.  3a–g). In these experiments NCL-
00016066 did not significantly affect the activity of wild-
type Pfnek-2 (Fig.  4a–g). In contrast, NCL-00016066 
Fig. 3 Phosphorylation of in vitro protein kinase substrates by 
Pfnek-2 and Pfnek-2(V24C). a, b Phosphorylation of the exogenous 
substrates myelin basic protein (MBP) and α-casein by Pfnek-2 and 
Pfnek-2(V24C). Shown is a Coomassie blue stained radioactive gel 
(a) and the resulting autoradiograph (b), which are representative of 
three experiments. The position of molecular weight markers (kDa) 
are shown
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acted in a dose-dependent manner to inhibit the activity 
of Pfnek-2(V24C), with an IC50 value of 501  nM [pIC50 
(M) value, 6.30 ± 0.25 (n = 3)] (Fig. 4c, d, f, g).
In order to investigate the mechanism of the inhibition 
of Pfnek-2(V24C) by NCL-00016066, the mutant kinase 
was pre-incubated with NCL-00016066 (20 µM) prior to 
immobilization on Ni–NTA beads, and unbound inhibi-
tor were removed by extensive washing. As a control, 
Pfnek-2 was similarly incubated with high concentrations 
of NCL-00016066 (20 µM), which gave partial inhibition 
of kinase activity, which was reversed following washout 
(Fig. 5a). In contrast, NCL-00016066 (20 µM) completely 
inhibited the activity of Pfnek-2(V24C) (Fig.  5b, c) in a 
manner that was not reversed by the washout procedure 
(Fig. 5b, c). These data indicated that Pfnek-2(V24C) was 
sensitive to NCL-00016066 inhibition and that inhibition 
of the mutant kinase by NCL-00016066 was irreversible 
(Fig. 5b, c).
Fig. 4 Inhibition of Pfnek-2 and Pfnek-2(V24C) kinase activity by NCL-00016066. a, b Representative experiment showing the effect of NCL-
00016066 (10 μM) on the activity of Pfnek-2 and Pfnek-2(V24C). Shown is the autoradiograph (a) and Coomassie blue stained radioactive gel (b). c, 
d Same as (a, b) except the concentration of NCL-00016066 is 1 μM. The position of molecular weight markers (kDa) are shown. e, f Quantification 
of the experiments shown in (a–d). Data shown is the mean ± SEM; n = 3. Data analysed using Students paired t test *p ≤ 0.05. g Concentration–
response curve for the activity of NCL-00016066 against Pfnek-2 and Pfnek-2(V24C). Data shown is the mean ± SEM; n = 3. Data analysed using 
students paired t-test *p ≤ 0.05
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Establishing the nature of the inhibition of the 
Pfnek‑2(V24C) mutant
In an effort to further characterize the nature of the inhi-
bition of the mutant Pfnek-2 with NCL-00016066, wild 
type Pfnek-2 or Pfnek-2(V24C) were pre-incubated with 
or without 100 µM NCL-00016066 and the intact protein 
subjected to analysis by mass spectrometry.
Pfnek-2 without inhibitor (black trace Fig. 6a; Table 1) 
showed charge state distributions containing 4–8 peaks 
that corresponded to different phosphorylation states. 
The addition of NCL-00016066 did not change the m/z 
ratio of Pfnek-2 (red trace Fig. 6a; Table 1). In contrast, 
Pfnek-2(V24C) showed a clear shift in the m/z ratio 
upon addition of NCL-00016066 (Fig.  6b; Table  1). The 
shift corresponded to a molecular weight change of 
315.03  ±  0.53  Da which is the mass of NCL-00016066 
(Table  1). This strongly suggests a covalent linkage of 
NCL-00016066 with the mutant kinase.
Table 1 shows the measured mass of the intact kinase 
[MW(Da)] and standard deviation, the predicted molec-
ular weight for each charge state distributions (Predicted 
MW), the number of phosphate groups (M + Phospho), 
and the difference between the predicted and measured 
molecular weight [D(Da)]. The values highlighted in red 
indicate the difference in molecular weight of the mutant 
kinase in the presence of NCL-00016066 where the 
∆(Da) value approximates to the molecular weight of the 
inhibitor.
Autophosphorylation of Pfnek‑2
Mass spectrometry analysis of the intact protein as 
described above indicated that Pfnek-2 undergoes 
Fig. 5 Irreversible inhibition of Pfnek-2(V24C) activity by NCL-
00016066. a, b Activity of NCL-00016066 (20 μM) against Pfnek-2 
(a) and Pfnek-2(V24C) (b) before and after wash out of the inhibitor. 
Shown are the autoradiographs (a, b). The position of molecular 
weight markers (kDa) are shown. c Quantification of three independ-
ent experiments indicating the effect of washing on Pfnek-2(V24C). 
Data shown is the mean ± S.E.M; n = 3. Data analysed using Students 
paired t-test *p ≤ 0.05
Fig. 6 Shift in molecular weight of Pfnek-2 V24C as determined 
by mass spectroscopy. Pfnek-2 wild-type without (black trace) and 
with (red trace) NCL-00016066 a show no differences in peaks of 
the mass to charge ratios (m/z) for any particular charge state and 
number of phosphate groups (Table 1). In contrast when the mutant 
is incubated with inhibitor (b), there is a shift to the right (red trace) 
compared to without inhibitor (black trace) indicative of an increase in 
mass of 315.03 ± 0.53 Da—the approximate weight of the inhibitor 
confirming covalent bonding of the inhibitor to cysteine 22. For the 
purposes of clarity, in each panel the red trace is shifted vertically with 
respect to the black trace
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multiple autophosphorylation events. Analysis of tryp-
tic phospho-peptides unequivocally identified three 
autophosphorylation sites, Ser20, Ser215 and Ser219 
(Fig.  7). Interestingly, these autophosphorylation sites 
appeared to be distinct from those identified in Hsnek2 
[29]. Only Ser20 is conserved in both Hsnek2 and 
Pfnek-2 but is not autophosphorylated in the human [29].
Discussion
The aim of the current study was to engineer Pfnek2 in 
a manner that would confer sensitivity of the kinase to 
a kinase inhibitor that otherwise would show low lev-
els of activity to wild type Pfnek2. This was achieved 
by mutating Val24 in the wild type Pfnek-2 to cysteine. 
This mutation confers susceptibility to the kinase inhibi-
tor NCL-00016066, and that the nature of this inhibition 
is likely through an irreversible covalent link of NCL-
00016066 with the modified cysteine.
Pfnek-2 is expressed predominantly in female game-
tocytes [10]. Transmission studies with the rodent 
malaria parasite Plasmodium berghei showed that para-
sites lacking the enzyme Pfnek-2 are able to undergo 
gametocytogenesis, gametogenesis and fertilization, 
but do not develop into ookinetes; this is likely due to 
a defect in meiosis, as pbnek-2− parasites appear to 
be unable to implement the pre-meiotic DNA replica-
tion that brings the DNA content to 4C in wild-type 
parasites, but remains 2C in the mutant parasites [10]. 
The demonstrated association of Pbnek-2 with micro-
tubule-like structures in the gametocyte [10] suggests 
that the impairment in DNA replication may be medi-
ated through improper spindle formation during the 
first round of meiotic DNA replication. Understanding 
the details of the molecular mechanisms that are regu-
lated by Pfnek-2 (including identifying substrates of the 
enzyme) would be greatly facilitated by a model system 
whereby Pfnek-2 activity can be selectively and rapidly 
inhibited. The current study, has taken advantage of the 
extensive efforts to develop inhibitors to Hsnek2, consid-
ered a validated target in cancer drug discovery, to estab-
lish a chemical genetic approach to the study of Pfnek-2.
Structural analysis of the Hsnek2 in complex with 
NCL-00016066 demonstrated that this inhibitor acts in 
an irreversible manner by covalent linkage to cysteine 22 
in the glycine rich loop. Interestingly, Pfnek-2 does not 
contain this cysteine, or any other cysteine, in this loop. 
Demonstrated here is the weak inhibitor activity of NCL-
00016066 against wild-type Pfnek-2 likely due to a lack 
of a cysteine in this position. Consistent with this notion 
is that NCL-00016066 showed potent inhibitory activity 
Table 1 Molecular mass of Pfnek-2, Pfnek-2(V24C) and NCL-00016066
Predicted molecular weight (Predicted MW) = mass of kinase + phosphorylation sites
Δ (Da) = difference between predicted MW and measured MW for each charged state distribution
M+ #phospho Charge state distribution MW (Da) Std Dev (Da) MW (calc) Δ (Da)
44+ 43+ 42+ 41+ 40+ 39+ 38+
Pfnek2+ vehicle
 5 882 903 924 947 971 995 1022 38,784 0.20 38,784 0.12
 6 884 905 926 949 973 998 1024 38,864 0.72 38,864 0.31
 7 886 907 928 951 975 1000 1026 38,944 0.68 38,944 0.30
 8 888 909 930 953 977 1002 1028 39,024 0.51 39,024 0.42
Pfnek2+ NCL-00016066
 5 882 903 924 947 971 995 1022 38,784 0.80 38,784 0.02
 6 884 905 926 949 973 998 1024 38,865 0.62 38,864 0.84
 7 886 907 928 951 975 1000 1026 38,944 0.75 38,944 0.43
 8 888 909 930 953 977 1002 1028 39,024 0.62 39,024 0.12
V24C+ vehicle
 5 883 903 924 947 971 995 1022 38,786 0.83 38,788 −1.58
 6 884 905 926 949 973 998 1024 38,866 0.58 38,868 −1.71
 7 886 907 928 951 975 1000 1026 38,946 1.27 38,948 −1.21
 8 888 909 930 953 977 1002 1028 39,028 2.12 39,028 0.23
V24C+ NCL-00016066
 5 890 910 932 955 979 1004 1030 39,103 1.77 38,788 315.30
 6 892 912 934 957 981 1006 1032 39,183 1.30 38,868 314.88
 7 893 914 936 959 983 1008 1034 39,262 1.35 38,948 314.35
 8 895 916 938 961 985 1010 1036 39,343 1.71 39,028 315.59
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Fig. 7 Autophosphorylation sites of Pfnek-2 as determined by mass spectroscopy. a Primary amino acid sequence of Pfnek-2. Sections in bold 
represent Pfnek-2 peptides observed in mass spectrometry experiments and in red are amino acids identified as being phosphorylated. b–e Repre-
sentative mass spectra and associated fragmentation tables are shown that cover the three identified phosphorylated residues (Ser-20, Ser-215, and 
Ser-219). f List of the phospho-peptides identified in the overall data set
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if a cysteine residue is introduced into the glycine-rich 
loop of Pfnek-2. Furthermore, this inhibition appeared to 
be irreversible, and mass spectrometry studies indicated 
that this is likely due to covalent modification of the vari-
ant kinase at the substituted cysteine.
Conclusions
Recent studies have deployed a chemical genetic 
approach to the study of PfPKG where parasites express-
ing a mutant form of the kinase that is resistant to inhibi-
tion by a selective PfPKG inhibitor was used to identify 
cellular targets and physiological roles of the kinase [28]. 
The engineering described here of a variant of Pfnek-2 
that can impart sensitivity to chemical inhibition now 
allows for a similar chemical genetic strategy for the 
study of Pfnek-2. In this instance, the introduction of the 
Pfnek-2(V24C) mutant into the gene locus of Pfnek-2 will 
generate a mutant parasite strain that expresses a vari-
ant of Pfnek-2 sensitive to inhibition by NCL-00016066. 
In this way NCL-00016066 can be used as a selective 
probe to define the cellular targets and physiological role 
of this kinase. Importantly NCL-00016066 will likely be 
selective for the engineered mutant parasite as there are 
no cysteine residues in the glycine rich loop of any of the 
other Pfneks.
In this way, the data presented here opens the door to 
investigating the essential role that Pfnek-2 plays in the 
transmission of malaria from the host to the mosquito 
vector and in doing so might inform on the mode of 
action of potential transmission-blocking drugs targeting 
this kinase.
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